Retracted: Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses - European Medical Journal

This site is intended for healthcare professionals

Continue

Retracted: Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses

Oncology
Download PDF

The publication of this infographic was funded by Pierre Fabre Laboratories. It is intended for nurses in countries where neratinib (NERLYNX) is marketed.

This infographic has now been retracted and a retraction statement has been published.

Retraction: Optimising Extended Adjuvant Neratinib Use in HER2+/HR+ Early Breast Cancer: Memo For Nurses

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.

We’ve noticed you’re accessing
from North/South America.